4.88 USD
▲-0.09+4.95%
2026-08-03
市值
$347.39M
市盈率
—
EPS
-1.74
股息率
—
52 周区间
1.21 – 6.95
成交量
788.63K
Beta
1.93
目标价
6.67
52W 低 1.2152W 高 6.95
价格走势
公司简介
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ...